Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%
Production / Operations Routine +

Albany Graphite Corp. Engages AppEco for Independent Market Research and Economic Analysis

Albany Graphite PEA Prep Advances Amidst Nasdaq Compliance Pressure and Price Collapse

By The Northwire Desk — AI Analysis Apr 16, 2026 · 10:56 ZEN · 0.63 Zentek Ltd.
Executive Summary
  • Albany Graphite Project: Zentek's subsidiary, Albany Graphite Corp., has engaged AppEco Inc. to conduct independent market research and economic analysis for the Albany Graphite Project in Ontario.
  • Study Scope: The study focuses on establishing independent pricing and demand data for high-purity graphite across nuclear, defense, battery, and industrial markets. It includes a valuation of 18 recoverable critical minerals (including rare earth elements) from the FBR scrubber exhaust.
  • PEA Timeline: Findings will feed into an economic model by Micon International; the Company anticipates publishing the Preliminary Economic Assessment (PEA) this summer (2026).
  • Technical Context: The project utilizes a chlorine-free electrothermal Fluidized Bed Reactor (FBR) capable of producing 5N+ purity graphite.
  • Triera Biosciences: Completed an Innovative Solutions Canada contract for H5N1 avian influenza and secured OCI funding to advance seasonal influenza candidates.
  • ZenGUARD/Altek: Initiated a pilot evaluation program with Quality Filters Inc. for air filtration media integration.
Material Impact
  • Incremental Progression: The engagement of AppEco is a logical follow-up to the April 9th announcement regarding Micon International's PEA preparation. It does not introduce new revenue streams or partnerships but reinforces the timeline for the upcoming PEA release expected in Summer 2026.
  • Co-Product Valuation: The mention of valuing 18 critical minerals from scrubber exhaust is a potential upside catalyst, but without specific recovery rates or market contracts disclosed yet, it remains speculative compared to the core graphite value proposition.
  • Market Disconnect: Despite multiple "Material - Positive" historical news items (Nuclear purity validation in Jan/Feb 2026, Litigation win in March 2026), the stock price has collapsed from ~$1.50 (April 2025) to $0.63 (April 2026). This indicates significant market skepticism regarding execution or liquidity concerns that outweighs fundamental progress.
  • Nasdaq Compliance Risk: The most critical risk remains the Nasdaq minimum bid price requirement ($1.00), with a deadline of August 24, 2026. At $0.63, the company must achieve a ~58% price increase in four months to avoid delisting, regardless of PEA progress.
  • Routine Classification: Given that the PEA engagement was previously announced (Feb/April 2026) and the market has already priced in the technical milestones without reward, this news is expected and incremental.
ZEN · Price
Company Overview
  • Zentek Ltd.: A diversified technology company with three core platforms: Albany Graphite, ZenGUARD (Air Filtration), and Triera Biosciences (Aptamer Technology).
  • Albany Graphite Project: The primary asset. Located in Ontario, it focuses on producing ultra-high-purity graphite (5N+) suitable for nuclear reactors, defense, and batteries. Independent testing has confirmed 99.9992% purity with Boron <3ppm.
  • ZenGUARD: Enhanced air filtration media targeting infectious aerosol removal (42% efficiency vs 16% untreated). Commercialization is being pursued via partnerships (e.g., Altek, Quality Filters) rather than direct manufacturing.
  • Triera Biosciences: Subsidiary developing aptamer-based therapeutics and diagnostics for influenza and other pathogens. Recently secured government contracts (ISC program) to fund development.
Read the original news release →

More from Zentek Ltd.

Jul 07, 2026 · 09:19

Zentek secures its first US commercial order, validating its pilot program while facing a Nasdaq delisting deadline at $0.67.

M&A / Property Jun 29, 2026 · 08:01

Zentek secures U.S. licensing for its ZenGUARD filtration media as the Albany project preliminary economic assessment nears completion.

M&A / Property Jun 26, 2026 · 09:28

Zentek Forms U.S. Joint Venture to Position Its Albany Ultra-High-Purity Graphite in the North American National-Security Supply Chain

M&A / Property Jun 09, 2026 · 11:12

Zentek secured a U.S. patent for its ZenGUARD graphene technology, though commercial execution and Nasdaq compliance remain critical challenges for the company.

Other May 27, 2026 · 09:10

Zentek closes $18M oversubscribed financing to advance Albany graphite PEA, but stock drifts below issue price amid Nasdaq compliance pressure.

Financings May 19, 2026 · 07:31

Zentek Secures Liquidity with Oversubscribed Offering Amid Nasdaq Compliance Pressure

Financings